Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
J Ocul Pharmacol Ther ; 29(10): 887-92, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24180629

ABSTRACT

PURPOSE: Gram-positive cocci and Propionibacterium acnes are widely reported agents of infectious postoperative endophthalmitis. This multicenter study was conducted to evaluate the eradication effectiveness and safety profile of levofloxacin 1.5% ophthalmic solution (LVFX 1.5%) for use in perioperative disinfection. METHODS: Patients who were scheduled for cataract surgery were enrolled. The perioperative regimen of LVFX 1.5% was administered 3 times daily as follows: preoperative 3 days; the day of surgery (in the morning, 1 h before surgery, and immediately after surgery); and postoperative 2 weeks. Conjunctival sac scrapings were collected 3 times in the observation period; before preoperative administration, before iodine eyewash on the day of surgery, and after completion of postoperative administration. Isolated and identified microbial strains were assessed for antibacterial susceptibility. RESULTS: One hundred patients were enrolled and data obtained from 96 patients (mean age, 72.7 ± 8.9 years). The preoperative eradication rate was 86.7% in total microbes. In the case of gram-positive cocci, the preoperative eradication rate was 100%, even though there were LVFX-registrant methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococcus, which had a high minimum inhibitory concentration against LVFX, such as 32 µg/mL. On the other hand, that of P. acnes was 78.3%. No acquired drug resistance was suspected in all strains. Adverse drug reactions occurred in 4.2% patients, and all were slight. CONCLUSIONS: For ophthalmic perioperative disinfection, the LVFX 1.5% ophthalmic solution showed a good safety profile, and critical eradication of gram-positive cocci, including the fluoroquinolone-resistant strains.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cataract Extraction/methods , Endophthalmitis/prevention & control , Eye Infections, Bacterial/prevention & control , Levofloxacin/therapeutic use , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Drug Resistance, Bacterial , Endophthalmitis/microbiology , Eye Infections, Bacterial/microbiology , Female , Gram-Positive Cocci/drug effects , Gram-Positive Cocci/isolation & purification , Humans , Levofloxacin/administration & dosage , Levofloxacin/adverse effects , Male , Microbial Sensitivity Tests , Middle Aged , Ophthalmic Solutions , Perioperative Care/methods , Postoperative Complications/prevention & control , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL